An RNA treatment targeting a rare genetic eye disease has posted disheartening phase 2/3 results, failing to significantly improve vision in those who received the drug.
Source: Drug Industry Daily
An RNA treatment targeting a rare genetic eye disease has posted disheartening phase 2/3 results, failing to significantly improve vision in those who received the drug.
Source: Drug Industry Daily